Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease

• Published in: International journal of molecular sciences 2024-01, Vol.25 (2), p.694
• Main Authors: Serrano-Martínez, Ignacio, Pedreño, Marta, Castillo-González, Julia, Ferraz-de-Paula, Viviane, Vargas-Rodríguez, Pablo, Forte-Lago, Irene, Caro, Marta, Campos-Salinas, Jenny, Villadiego, Javier, Peñalver, Pablo, Morales, Juan Carlos, Delgado, Mario, González-Rey, Elena
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Brain; Brain-derived neurotrophic factor; Cell death; cortistatin; Dopamine; Gene expression; gliosis; Medical research; Medicine, Experimental; Mice; Neurodegeneration; neurodegenerative diseases; neuroinflammation; Neurons; Neuropeptides; Neurophysiology; Neurotoxins; Oxidative stress; Parkinson Disease - drug therapy; Parkinson's disease; Proteins
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25020694

Parkinson's disease (PD) is a complex disorder characterized by the impairment of the dopaminergic nigrostriatal system. PD has duplicated its global burden in the last few years, becoming the leading neurological disability worldwide. Therefore, there is an urgent need to develop innovative approaches that target multifactorial underlying causes to potentially prevent or limit disease progression. Accumulating evidence suggests that neuroinflammatory responses may play a pivotal role in the neurodegenerative processes that occur during the development of PD. Cortistatin is a neuropeptide that has shown potent anti-inflammatory and immunoregulatory effects in preclinical models of autoimmune and neuroinflammatory disorders. The goal of this study was to explore the therapeutic potential of cortistatin in a well-established preclinical mouse model of PD induced by acute exposure to the neurotoxin 1-methil-4-phenyl1-1,2,3,6-tetrahydropyridine (MPTP). We observed that treatment with cortistatin mitigated the MPTP-induced loss of dopaminergic neurons in the substantia nigra and their connections to the striatum. Consequently, cortistatin administration improved the locomotor activity of animals intoxicated with MPTP. In addition, cortistatin diminished the presence and activation of glial cells in the affected brain regions of MPTP-treated mice, reduced the production of immune mediators, and promoted the expression of neurotrophic factors in the striatum. In an in vitro model of PD, treatment with cortistatin also demonstrated a reduction in the cell death of dopaminergic neurons that were exposed to the neurotoxin. Taken together, these findings suggest that cortistatin could emerge as a promising new therapeutic agent that combines anti-inflammatory and neuroprotective properties to regulate the progression of PD at multiple levels.